SCHEMBL24254517

SCHEMBL24254517

CC(=O)Nc1cc(S(=O)(=O)N(C)C)ccc1OC(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 1/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 7/20 0.48
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
GAA P10253 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RECQL P46063 1/20 0.45
ABCC9 O60706 1/20 0.45
ABCC8 Q09428 1/20 0.45
KCNJ11 Q14654 1/20 0.45
KCNJ8 Q15842 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24254516 0.84 KMT2A (0.51) GSTO1LMNAALDH1A1MAPK1MEN1
SCHEMBL24254564 0.79 ALDH1A1 (0.51) GSTO1LMNASMN1; SMN2ALDH1A1MAPK1
SCHEMBL9973781 0.76 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1MAPK1GAA
SCHEMBL17681593 0.76 ALDH1A1 (0.56) ALDH1A1GAAMEN1KMT2ARECQL
SCHEMBL24254518 0.75 ALDH1A1 (0.49) GSTO1ALDH1A1TSHRMEN1KMT2A
SCHEMBL17681780 0.75 CYP1A2 (0.70) ALDH1A1TSHRMAPK1MEN1KMT2A
SCHEMBL9973787 0.75 ALDH1A1 (0.55) ALDH1A1TSHRMEN1KMT2ARECQL
SCHEMBL1527189 0.75 ALDH1A1 (0.55) LMNASMN1; SMN2ALDH1A1RECQLL3MBTL1
SCHEMBL19459414 0.74 MAPT (0.54) LMNASMN1; SMN2ALDH1A1TSHRMAPK1
SCHEMBL24254513 0.74 ALDH1A1 (0.56) LMNASMN1; SMN2ALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-31 US disclosed
WO-2022035804-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271918-A1 SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP1 GSTO1 1853/4885LMNA 3727/4885SMN1; SMN2 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.